Patient characteristics for each donor type
| . | CB (n = 1915) . | MRD (n = 1772) . | 1-MMRD (n = 225) . | MUD (n = 1742) . | 1-MMUD (n = 963) . | P . |
|---|---|---|---|---|---|---|
| Age at HSCT, median (range), y | 44 (0-85) | 40 (0-74) | 32 (0-68) | 45 (0-72) | 44 (0-71) | |
| 0-20 | 419 (21.9) | 294 (16.6) | 75 (33.3) | 213 (12.2) | 149 (15.5) | <.01 |
| 21-40 | 415 (21.7) | 618 (34.9) | 66 (29.3) | 470 (27.0) | 258 (26.8) | |
| 41-60 | 667 (34.8) | 707 (39.9) | 62 (27.6) | 754 (43.3) | 435 (45.1) | |
| ≥61 | 414 (21.6) | 153 (8.6) | 22 (9.8) | 305 (17.5) | 121 (12.6) | |
| Year of HSCT | ||||||
| 2008-2011 | 734 (38.3) | 848 (47.9) | 112 (49.8) | 707 (40.6) | 373 (38.7) | <.01 |
| 2012-2015 | 1181 (61.7) | 924 (52.1) | 113 (50.2) | 1035 (59.4) | 590 (61.3) | |
| Patient sex | ||||||
| Male | 1037 (54.2) | 1005 (56.7) | 140 (62.2) | 984 (56.5) | 540 (56.1) | .03 |
| Female | 878 (45.8) | 767 (43.3) | 85 (37.8) | 758 (43.5) | 423 (43.9) | |
| Disease | ||||||
| ALL | 761 (39.7) | 734 (41.4) | 93 (41.3) | 681 (39.1) | 393 (40.8) | .66 |
| AML | 1154 (60.3) | 1038 (58.6) | 132 (58.7) | 1061 (60.9) | 570 (59.2) | |
| Disease status at HSCT | ||||||
| CR1 | 1375 (72.2) | 1427 (80.7) | 153 (68.0) | 1347 (77.5) | 692 (71.9) | .01 |
| ≥CR2 | 530 (27.8) | 342 (19.3) | 72 (32.0) | 392 (22.5) | 271 (28.1) | |
| Unknown | 10 (0.5) | 3 (0.2) | 0 (0.0) | 3 (0.2) | 0 (0.0) | <.01 |
| ECOG-PS | ||||||
| 0-2 | 1801 (94.0) | 1711 (96.6) | 211 (93.8) | 1678 (96.3) | 917 (95.2) | <.01 |
| 3-4 | 104 (5.5) | 57 (3.2) | 14 (6.2) | 60 (3.5) | 46 (4.8) | |
| Unknown | 10 (0.5) | 4 (0.2) | 0 (0.0) | 4 (0.2) | 0 (0.0) | |
| Donor source | ||||||
| BM | — | 808 (45.6) | 110 (48.9) | 1699 (97.5) | 961 (99.8) | <.01 |
| PB | — | 964 (54.4) | 115 (51.1) | 43 (2.5) | 2 (0.2) | |
| HLA disparity | ||||||
| Match | 251 (13.1) | 1772 | — | 1742 | — | — |
| Mismatch | 1664 (86.9) | — | 225 | — | 963 | |
| Conditioning regimen | ||||||
| Myeloablative | 1111 (58.0) | 1326 (74.8) | 149 (66.2) | 1145 (65.7) | 640 (66.5) | <.01 |
| BU/TBI based | 188/923 | 302/1024 | 41/108 | 263/882 | 131/509 | |
| Reduced intensity | 801 (41.8) | 445 (25.1) | 76 (33.8) | 594 (34.1) | 323 (33.5) | |
| Unknown | 3 (0.2) | 1 (0.1) | 0 (0.0) | 3 (0.2) | 0 (0.0) | |
| GVHD prophylaxis | ||||||
| Tac based | 1347 (70.3) | 330 (18.6) | 187 (83.1) | 1484 (85.2) | 868 (90.2) | <.01 |
| CyA based | 553 (28.9) | 1405 (79.3) | 34 (15.1) | 236 (13.6) | 83 (8.6) | |
| Others/unknown | 15 (0.8) | 37 (2.1) | 4 (1.8) | 22 (1.2) | 12 (1.2) | |
| Use of ATG | ||||||
| ATG(−) | 1862 (97.2) | 1754 (99.0) | 153 (68.0) | 1709 (98.1) | 860 (89.3) | <.01 |
| ATG(+) | 53 (2.8) | 18 (1.0) | 72 (32.0) | 33 (1.9) | 103 (10.7) |
| . | CB (n = 1915) . | MRD (n = 1772) . | 1-MMRD (n = 225) . | MUD (n = 1742) . | 1-MMUD (n = 963) . | P . |
|---|---|---|---|---|---|---|
| Age at HSCT, median (range), y | 44 (0-85) | 40 (0-74) | 32 (0-68) | 45 (0-72) | 44 (0-71) | |
| 0-20 | 419 (21.9) | 294 (16.6) | 75 (33.3) | 213 (12.2) | 149 (15.5) | <.01 |
| 21-40 | 415 (21.7) | 618 (34.9) | 66 (29.3) | 470 (27.0) | 258 (26.8) | |
| 41-60 | 667 (34.8) | 707 (39.9) | 62 (27.6) | 754 (43.3) | 435 (45.1) | |
| ≥61 | 414 (21.6) | 153 (8.6) | 22 (9.8) | 305 (17.5) | 121 (12.6) | |
| Year of HSCT | ||||||
| 2008-2011 | 734 (38.3) | 848 (47.9) | 112 (49.8) | 707 (40.6) | 373 (38.7) | <.01 |
| 2012-2015 | 1181 (61.7) | 924 (52.1) | 113 (50.2) | 1035 (59.4) | 590 (61.3) | |
| Patient sex | ||||||
| Male | 1037 (54.2) | 1005 (56.7) | 140 (62.2) | 984 (56.5) | 540 (56.1) | .03 |
| Female | 878 (45.8) | 767 (43.3) | 85 (37.8) | 758 (43.5) | 423 (43.9) | |
| Disease | ||||||
| ALL | 761 (39.7) | 734 (41.4) | 93 (41.3) | 681 (39.1) | 393 (40.8) | .66 |
| AML | 1154 (60.3) | 1038 (58.6) | 132 (58.7) | 1061 (60.9) | 570 (59.2) | |
| Disease status at HSCT | ||||||
| CR1 | 1375 (72.2) | 1427 (80.7) | 153 (68.0) | 1347 (77.5) | 692 (71.9) | .01 |
| ≥CR2 | 530 (27.8) | 342 (19.3) | 72 (32.0) | 392 (22.5) | 271 (28.1) | |
| Unknown | 10 (0.5) | 3 (0.2) | 0 (0.0) | 3 (0.2) | 0 (0.0) | <.01 |
| ECOG-PS | ||||||
| 0-2 | 1801 (94.0) | 1711 (96.6) | 211 (93.8) | 1678 (96.3) | 917 (95.2) | <.01 |
| 3-4 | 104 (5.5) | 57 (3.2) | 14 (6.2) | 60 (3.5) | 46 (4.8) | |
| Unknown | 10 (0.5) | 4 (0.2) | 0 (0.0) | 4 (0.2) | 0 (0.0) | |
| Donor source | ||||||
| BM | — | 808 (45.6) | 110 (48.9) | 1699 (97.5) | 961 (99.8) | <.01 |
| PB | — | 964 (54.4) | 115 (51.1) | 43 (2.5) | 2 (0.2) | |
| HLA disparity | ||||||
| Match | 251 (13.1) | 1772 | — | 1742 | — | — |
| Mismatch | 1664 (86.9) | — | 225 | — | 963 | |
| Conditioning regimen | ||||||
| Myeloablative | 1111 (58.0) | 1326 (74.8) | 149 (66.2) | 1145 (65.7) | 640 (66.5) | <.01 |
| BU/TBI based | 188/923 | 302/1024 | 41/108 | 263/882 | 131/509 | |
| Reduced intensity | 801 (41.8) | 445 (25.1) | 76 (33.8) | 594 (34.1) | 323 (33.5) | |
| Unknown | 3 (0.2) | 1 (0.1) | 0 (0.0) | 3 (0.2) | 0 (0.0) | |
| GVHD prophylaxis | ||||||
| Tac based | 1347 (70.3) | 330 (18.6) | 187 (83.1) | 1484 (85.2) | 868 (90.2) | <.01 |
| CyA based | 553 (28.9) | 1405 (79.3) | 34 (15.1) | 236 (13.6) | 83 (8.6) | |
| Others/unknown | 15 (0.8) | 37 (2.1) | 4 (1.8) | 22 (1.2) | 12 (1.2) | |
| Use of ATG | ||||||
| ATG(−) | 1862 (97.2) | 1754 (99.0) | 153 (68.0) | 1709 (98.1) | 860 (89.3) | <.01 |
| ATG(+) | 53 (2.8) | 18 (1.0) | 72 (32.0) | 33 (1.9) | 103 (10.7) |
Data are presented as n (%), unless otherwise indicated.
—, not applicable; BU, busulfan; CyA, cyclosporin A; TBI, total body irradiation; Tac, tacrolimus.